comprehensive -WSS

comprehensive

author：explore 2025-10-01 00:46:57 - browse：881

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Why getting cancer drugs just got harder for rural patients

hotspot

WSS

Congress gives doctors Medicare pay bump

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Listen: Who gets the credit for GLP

Congress gives doctors Medicare pay bump

Scientists unlock the key to scar

AstraZeneca loses challenge to Medicare drug price negotiation

hotspot

comprehensive

hotspot

Continuity nursing helped my family in our darkest PICU moments

International team creates first chimeric human

Dobbs anniversary: the lost opportunity of abortion as health care

Biotech companies concerned about China biosecurity crackdown

Cancer drug shortages should be causing more outrage

How the Dana

Medical records are filled with copy

WHO recommends dropping component of many flu vaccines

At least 13 dead in Texas as scorching temps continue

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Wikipedia

RSV vaccines may be linked to small increased risk of developing GBS

Covid vaccines: Private market messier than government rollout

International team creates first chimeric human

Kaiser Permanente unions announce official strike date

Did you have Obamacare on your GOP debate bingo card?

Shingles, which affected Dianne Feinstein, is on the rise

explore

hotspot

knowledge

hotspot